Reducing Oxidative Stress at the Source
Glucox Biotech AB activity focuses on developing pharmaceutical treatments, targeting specific sources of reactive oxygen that causes oxidative stress in diabetes with its complications, based on the company’s proprietary rights covering the rights to develop pharmaceutical substances for treating disorders related to oxidative stress on the basis of reactive oxygen species produces by NAD(P)H-oxidase, primarily NOX4. Recent literature establishes NOX4 as an important factor also in stroke and heart infarction. Therefore, Glucox Biotech also develops NOX4 inhibitors for the treatment of these conditions.
The idea behind Glucox Biotech’s therapies is to reduce oxidative stress by preventing the intracellular formation of reactive oxygen species and thus improve blood glycemic control and also decrease the critical risks and delay progression of complications in type 2 patients as well as cellular damage in stroke and heart infarction.
Glucox Biotech owns several patents covering the exclusive rights to develop pharmaceutical substances for treating insulin resistance and diabetes on the basis of reducing reactive oxygen species produces by NAD(P)H-oxidase (NOX4).
As off today, Glucox Biotech (GB) collaborates with European academic groups in the following areas:
– Investigation of GB Nox4 inhibitors in fibros assay
– Investigation of GB Nox4 inhibitors in Marfans syndrome
– Investigation of GB Nox4 inhibitors in protection of beta-cells in overfeed mice.
– Investigation of GB Nox4/Nox2 inhibitor in protection heart at ischemic stroke.
– Investigation of GB Nox4 inhibitor in ischemic stroke brain
– Investigation of Nox4 role in liver disease and cancer
News in brief
GLUCOX AT GORDON CONFERENCE: Glucox’ Head of Research, Per Wikström, was invited speaker attending a Gordon Conference, June 5-10, 2016, and presented the SAR development of the latest highly selective Glucox´ Nox4 inhibitors. Structure activity relationship (SAR) was determined using Nox4 membrane- and whole cell overexpressing Nox4-assay. Two of the most interesting Nox4 inhibitors that were presented have the following specification regarding selectivity towards other Nox iso forms: GLX7013114 with 0.3 microM (IC50 Nox4) and the selectivity 22 microM (IC50 Nox1) and for GLX7013107 with 2.4 microM (IC50 Nox4) and the selectivity 44 microM (IC50 Nox1). Both compound demonstrated more or less no inhibiting capability at all towards Nox2 and Nox5 as well as for Xanthine oxidase. No internal reducing capability could be determined.
GLUCOX´ CEO PRESENTED ON NOVEL COMPOUNDS: Erik Walum gave a presentation titled: ”Identification and characterization of novel small-molecule Nox inhibitors” at the 2nd Biotech Hanse Forum in Stockholm, June 6, 2016.
NEW PUBLICATION ON GLUCOX COMPOUND: E. Anvari, P. Wikström, E. Walum & N. Welsh; The novel NADPH oxidase inhibitor GLX351322 counteracts glucose intolerance in high-fat diet-treated C57BL/6 mice. Free Radical Research, 2015; Early on line: 1-11.
GLUCOX´ CEO PRESENTED ON NOVEL COMPOUND: Erik Walum gave a presentation titled : ”Use of in vitro methods in the development of a Nox4/Nox2-inhibitor (GLX481304) for the protection of oxidative stress” at the SSCT-Swetox Workshop: Mechanisms, markers and models – the 3M strategy in risk assessment, October 13 – 15, 2015, at Bommersvik, Järna.
GLUCOX´CEO PRESENTED IN MEETING ON OUTSOURCING: CEO Erik Walum presented a paper titled: ”Hit-to-lead compound development in a dynamic life science ecosystem” at the PharmaOutsourcing conference at Stockholm Waterfront, December 9, 2015.
EU-ROS – A COST ACTION: This action is one of the largest actions in the EU COST program. The action started with 26 European countries represented and has since been growing with other representatives invited from outside Europe. This organization exchange knowledge regarding research around specific sources of ROS that is linked to diseases such as diabetes and diabetic complications, neurodegenerative diseases (Alzheimer, Parkinson, Huntington, Amyotrophic lateral sclerosis, Schizophrenia), stroke and cancer. The action stimulates all kinds of collaborations such as academic as well as business deals. Glucox Biotech AB takes an active part sharing its Nox inhibitors for academic discovery and in return using this information for drug development into successful and safe pharmaceuticals.
Glucox’ Head of Research, Per Wikström, took part in the following EU-ROS meeting: April 21-24, 2015 in Munich, Germany and gave a presentation with the title: ”Identification and characterization of novel small-molecule Nox inhibitors”. Another EU-ROS meeting was held on October 22-24, 2015 in Bucharest, Romania.